1Yagil Y, Yagil C. Insights into pharmacogenomics and its impact upon immunosuppressive therapy. Transplant Immunol, 2002, 9:203-209.
2Min DI, Ellingrod VL. Association of the CYP3A4 * 1B5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit, 2003, 25:305-309.
3Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4in Chinese. Drug Metab Dispos, 2001, 29:268-273.
4Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant, 2003, 3:477-483.
5Macphee IA, Federicks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement.Transplantation, 2002, 74:1486-1489.
6Von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism(CYP3A4-V allele)on dose-adjusted cyclosporine A trough concentrations of rejection incidence in stable renal transplant recipients. Cli
7Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity indiced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation, 2002, 74: 571 -578.
8Brogan IJ, Pravica V, Hutchinson Ⅳ. Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2.Transplant Immunol, 2000, 8:139-141.
9Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol, 1999, 126:1075-1082.
10Huang YH, Galijatovic A, Nguyen N, et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8 * 1, UGT1A 8* 2 and UGT1A8*3. Pharmacogenetics,2002,12: 287-297.
3Cattaneo D,Perico N,Remuzzi G.From pharmacokinetics to pharmacogenomics:a new approach to tailor immunosuppressive therapy.Am J Transplant,2004,4:299-310.
4Thervet E,Pfeffer P,Scolari MP,et al.Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.Transplantation,2003,76:903-908.
5Levy G,Villamil F,Samuel D,et al.Results of lis2t,a multicenter,randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.Transplantation,2004,77:1632-1638.
6Dong JH,Chen G,Chen YC,et al.Validation assessment and target level determination of cyclosporine microemulsion with C2 monitoring in Chinese adult liver transplant recipients.Liver Transplantation,2004,10:5.
7Del Tacca M.Prospects for personalized immunosuppression:pharmacologic tools.Transplant Proc,2004,36:687-689.
8Evans WE,Relling MV.Moving towards individualized medicine with pharmacogenomics.Nature,2004,249:464-468.
9Fredericks S,Holt DW.Pharmacogenomics of immunosuppressive drug metabolism.Curr Opin Nephrol Hypertens,2003,12:607-613.
10Brogan IJ,Pravica V,Hutchinson IV.Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2.Transplant Immunol,2000,8:139-141.
